August 25, 2021 5:43pm

News: BioLife Solutions (BLFS) will be added to the S&P SmallCap 600 Index effective prior to the opening of trading on Monday, August 30, 2021.

The Biostage (BSTG) Chronicles: Wednesday, another 18,710 shares traded (+$0.16 to $2.21) after Tuesday’s 15,777 shares traded to prop the $2.05 (+$0.16) share price following Monday’s 38,354 shares (+$0.68 to $1.89) traded following months of 100 to 1,100 daily trading volume. Is it all about exercising $2.00 warrants from multiple private placements to raise any cash for a clinical trial (with an IND aged by 1.5 years) that never began?

  • WHAT is BSTG’s value proposition, after all the share price pumping? WHERE is the SEC?

Pre-open indications: 3 MISS and 4 HITs

My comments try to distinguish the temporary from real pricing digression or progress.

Who else is tracking a broad representative index of cell and gene therapy equities – the facts are supported by real numbers?


The Dow closed UP +39.24 points (+0.11%); the S&P closed UP +9.96 points (+0.22%) while the Nasdaq closed UP +22.06 points (+0.15%)

 

Henry’omics:

U.S. stocks climbed higher Wednesday as the 10-year Treasury yield climbed higher.

  • The yield on the benchmark 10-year Treasury note climbed to 1.341% Wednesday, its highest level since earlier in the month when it yielded as much as 1.364%.

Taper talk is the worry, but if inflation continues to run hot and economic data continues to be mixed the timing of tapering could get pushed,” noted Lindsey Bell, chief investment strategist at Ally Invest. “It’s unlikely that the Fed will force a taper on an economy that isn’t ready, and the outlook is becoming less certain with the rise of the Delta variant.” <CNBC>

  • Fed Chair Powell is slated to make remarks on Friday.

 

RegMed/Stem/Cell and Gene therapy’s 35 covered equities’ Advance/Decline (A/D) lines:

  • Wednesday opened negative at 13/20, 1 flat and 1 acquired, flipped positive at the mid-day at 18/16 and 1 acquired, ending with a positive close of 20/13, 1 flat and 1 acquired;

 

RegMed Investors’ (RMi) pre-open: “remember the mantra, new market and sector highs and I usually say bye but, there are a few “moves” out there” …  https://www.regmedinvestors.com/articles/12065

 

The Biostage (BSTG) Chronicles: “Facts from filed 10-Q” … https://www.regmedinvestors.com/articles/12055

 

Q2/21 Earnings releases … https://www.regmedinvestors.com/articles/11542  â€¦ to date:

  • Net Income: 3 and Net losses: 23

 

Key Metrics:

  • Sector volume was LOW with 2 of the 20-upside having higher than the 3-month average volume with very LOW volume of 3 of 13-downside having higher than the 3-month average volume;
  • Wednesday’s percentage (%) of the 20-upside were +0.28% (AGTC) to +19.62% (BLFS) while the 13-downside -0.19% (RGNX) to -5.72% (BLCM);

 

The Biostage (BSTG) Chronicles: Wednesday traded 18,472 shares traded (+$0.16 to $2.21) after Tuesday closed up +$0.28 with 10,590 shares trade after Monday’s +$0.68 with 38,354 shares traded following Friday’s -$0.07 with 570 shares traded, Thursday’s flat at with 50 shares traded, and last Wednesday’s closing down -$0.10 with 739 shares traded.

  • Today is just another fact, how the share trades with the “push/promote” - another typical example

 

Pre-open Indications: 4 HITs <BUY: BioLife Solutions (BLFS +$9.12), CRISPR Therapeutics (CTSP -$0.66), Intellia Therapeutics (NTLA -$3.86), Pluristem (PSTI -$0.11)> 3 MISS < Regenxbio (RGNX -$0.06), Biostage (BSTG +$0.16) – pumped and promoted, Editas Medicine (EDIT +$0.87)>;

 

There are clear winners and losers

Jumping with share pricing momentum:

  • BioLife Solutions (BLFS), Alnylam Pharmaceuticals (ALNY) - again, Ultragenyx (RARE) – yet another again, Fate Therapeutics (FATE), Editas Medicine (EDIT) to name 5 of the 20 inclining of the 35 covered

Hammered in today’s market:

  • Intellia Therapeutics (NTLA), CRISPR Therapeutics (CRSP), Ionis Pharmaceuticals (IONS), Global Blood Therapeutics (GBT), Regenxbio (RGNX) to name 5 of the 13 declining of the 35 covered

 

Wednesday’s (10 of 20) incliners:

  • BioLife Solutions (BLFS +$9,12 after Tuesday’s -$0.27 and Monday’s +$1.38);
  • Alnylam Pharmaceuticals (ALNY +$3.02 after Tuesday’s +$3.50);
  • Ultragenyx (RARE +$2.76 after Tuesday’s +$2.73 after Monday’s +$4.49);
  • Fate Therapeutics (FATE +$1.41 after Tuesday’s -$0.74 and Monday’s +$5.26);
  • Vericel (VCEL +$1.06 after Tuesday’s +$0.20 and Monday’s +$2.31),
  • Editas Medicine (EDIT +$0.87 after Tuesday’s -$0.64 and Monday’s +$4.98);
  • uniQure NV (QURE +$0.65);
  • Cellectis SA (CLLS -$0.21);
  • bluebird bio (BLUE -$0.15);
  • Sage Therapeutics (SAGE +$0.30 after Tuesday’s +$0.31);

Wednesday’s (13 of 13) decliners:

  • Intellia Therapeutics (NTLA -$3.86 after Tuesday’s +$4.28 and Monday’s +$8.75);
  • Global Blood Therapeutics (GBT -$0.66 after Tuesday’s +$0.56 and Monday’s +$1.18);
  • CRISPR Therapeutics (CRSP -$0.66 after Tuesday’s +$1.44 and Monday’s +$7.80);
  • Ionis Pharmaceuticals (IONS -$0.44 after Tuesday’s +$0.95 and Monday’s -$0.23);
  • Bellicum Pharmaceuticals (BLCM -$0.19 after Tuesday’s +$0.28);
  • Chinook Therapeutics (KDNY -$0.12);
  • Pluristem (PSTI -$0.11);
  • MiMedx (MDXG -$0.10 after Tuesday’s +$0.27);
  • Brainstorm Cell Therapeutics (BCLI -$0.06);
  • Regenxbio (RGNX -$0.06 after Tuesday’s-$0.13 and Monday’s +$2.13);
  • Precigen (PGEN -$0.04 after Tuesday’s -$0.24);
  • Athersys (ATHX -$0.03 after Tuesday’s -$0.03);
  • Solid Biosciences (SLDB -$0.02);

Closing – 1 –ReNeuron (RENE.L) and 1 -Stemline Therapeutics (STML) – acquired

 

Stats:

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Wednesday, the IBB closed up +0.67% and XBI closed up +1.10%

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Wednesday was down -0.43 points or -2.50% at 16.79

Upside volume:

  • Wednesday:  2 out of the 20-upside had higher than the 3-month average volume;

Downside volume:

  • Wednesday: 3 out of the 13-downside had higher than the 3-month average volume;

Percentage (%) movement/range statistics: price versus percentage …

  • Wednesday’s percentage (%) of the 20-upside were +0.28% (AGTC) to +19.62% (BLFS) while the 13-downside -0.19% (RGNX) to -5.72% (BLCM);

 

August, the second month of Q3/21:

  • Wednesday closed positive with 20 advancers, 13 decliners, 1 flat and 1 acquired
  • Tuesday closed positive with 21 advancers, 12 decliners, 1 flat and 1 acquired
  • Monday (8/23) closed positive with 32 advancers, 1 decliner, 1 flat and 1 acquired

 

The BOTTOM LINE: As I had stated, “Investor conviction and any trust is being challenged even as the sector rises and falls, I … still believe a … “conflagration” is coming” – it seems to be started …

Reiterating, being overbought sets-up another partial “BUYING/SELLING “condition”.

When you’re on a roller coaster, the only thing you can be sure of is you’ll end up back where you started.

Q2 reporting season has essentially run its course; although a few remain with my questions of WHY so late …?

A tool that hasn’t resonated … guidance is one factor of the sector.

I am keeping an eye on “runways” … as 2024 seems to be timing factor for most.

I’m STILL a “beware or the cautious man” whose focus has always been “warning analysis” … earnings’ season is NOT over … my advice, trim and skim any new highs if one can!”

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

Regulation Analyst Certification ("Reg AC"): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.